These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 17398318)

  • 1. Accounting for restart rates in evaluating persistence with ocular hypotensives.
    Schwartz GF; Platt R; Reardon G; Mychaskiw MA
    Ophthalmology; 2007 Apr; 114(4):648-52. PubMed ID: 17398318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility and efficacy of a mass switch from latanoprost to bimatoprost in glaucoma patients in a prepaid Health Maintenance Organization.
    Law SK; Song BJ; Fang E; Caprioli J
    Ophthalmology; 2005 Dec; 112(12):2123-30. PubMed ID: 16225924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension.
    Orzalesi N; Rossetti L; Bottoli A; Fogagnolo P
    Ophthalmology; 2006 Feb; 113(2):239-46. PubMed ID: 16458092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physicians' treatment decisions, patient persistence, and interruptions in the continuous use of prostaglandin therapy in glaucoma.
    Hahn SR; Kotak S; Tan J; Kim E
    Curr Med Res Opin; 2010 Apr; 26(4):957-63. PubMed ID: 20163296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistence and adherence with topical glaucoma therapy.
    Nordstrom BL; Friedman DS; Mozaffari E; Quigley HA; Walker AM
    Am J Ophthalmol; 2005 Oct; 140(4):598-606. PubMed ID: 16226511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of practice patterns for the care of open-angle glaucoma compared with claims data: the Glaucoma Adherence and Persistency Study.
    Quigley HA; Friedman DS; Hahn SR
    Ophthalmology; 2007 Sep; 114(9):1599-606. PubMed ID: 17572498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines.
    Stewart WC; Konstas AG; Nelson LA; Kruft B
    Ophthalmology; 2008 Jul; 115(7):1117-1122.e1. PubMed ID: 18082886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on circadian intraocular pressure.
    Rossetti L; Karabatsas CH; Topouzis F; Vetrugno M; Centofanti M; Boehm A; Viswanathan A; Vorwerk C; Goldblum D
    Ophthalmology; 2007 Dec; 114(12):2244-51. PubMed ID: 17459480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient persistency with ocular prostaglandin therapy: a population-based, retrospective study.
    Reardon G; Schwartz GF; Mozaffari E
    Clin Ther; 2003 Apr; 25(4):1172-85. PubMed ID: 12809964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials.
    Aptel F; Cucherat M; Denis P
    J Glaucoma; 2008 Dec; 17(8):667-73. PubMed ID: 19092464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inter-visit intraocular pressure range: an alternative parameter for assessing intraocular pressure control in clinical trials.
    Varma R; Hwang LJ; Grunden JW; Bean GW
    Am J Ophthalmol; 2008 Feb; 145(2):336-42. PubMed ID: 18222194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs.
    Bournias TE; Lai J
    Ophthalmology; 2009 Sep; 116(9):1719-24. PubMed ID: 19592108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measurement of persistence and adherence to regimens of IOP-lowering glaucoma medications using pharmacy claims data.
    Wilensky J; Fiscella RG; Carlson AM; Morris LS; Walt J
    Am J Ophthalmol; 2006 Jan; 141(1 Suppl):S28-33. PubMed ID: 16389058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A gap analysis approach to assess patient persistence with glaucoma medication.
    Lee PP; Walt JG; Chiang TH; Guckian A; Keener J
    Am J Ophthalmol; 2007 Oct; 144(4):520-4. PubMed ID: 17692273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the role of travoprost 0.004% ophthalmic solution in the management of open angle glaucoma and ocular hypertensive patients.
    Chiselită D;
    Oftalmologia; 2007; 51(2):81-6. PubMed ID: 17937041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of long-term intraocular pressure fluctuation in patients treated with bimatoprost or latanoprost.
    Simmons ST; Bernstein P; Hollander DA
    Am J Ophthalmol; 2008 Sep; 146(3):473-7. PubMed ID: 18561893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of latanoprost, bimatoprost, and travoprost on circadian variation of intraocular pressure in patients with open-angle glaucoma.
    Yildirim N; Sahin A; Gultekin S
    J Glaucoma; 2008; 17(1):36-9. PubMed ID: 18303382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy.
    Denis P; Lafuma A; Khoshnood B; Mimaud V; Berdeaux G
    Curr Med Res Opin; 2007 Mar; 23(3):601-8. PubMed ID: 17355741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of new coding for dry eye and ocular infection in open-angle glaucoma and ocular hypertension patients treated with prostaglandin analogs: retrospective analysis of three medical/pharmacy claims databases.
    Schwartz GF; Kotak S; Mardekian J; Fain JM
    BMC Ophthalmol; 2011 Jun; 11():14. PubMed ID: 21672240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use.
    Robin AL; Novack GD; Covert DW; Crockett RS; Marcic TS
    Am J Ophthalmol; 2007 Oct; 144(4):533-40. PubMed ID: 17686450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.